Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases
FEBS Open Bio · 2024-01 · 14 (1) · 96-111
DOI: 10.1002/2211-5463.13730 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 30.11.2023. Verfasst von Ping Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Melanoma, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting STOPhersentumoren.nl.
Abstract (Originalsprache)
BRAF V600 ‐mutated melanoma brain metastases (MBMs) are responsive to BRAF inhibitors, but responses are generally less durable than those of extracranial metastases. We tested the hypothesis that the drug efflux transporters P‐glycoprotein (P‐gp; ABCB1) and breast cancer resistance protein (BCRP; ABCG2) expressed at the blood–brain barrier (BBB) offer MBMs protection from therapy. We intracranially implanted A375 melanoma cells in wild‐type (WT) and Abcb1a/b;Abcg2 −/− mice, characterized the tumor BBB, analyzed drug levels in plasma and brain lesions after oral vemurafenib administration, and determined the efficacy against brain metastases and subcutaneous lesions. Although contrast‐enhanced MRI demonstrated that the integrity of the BBB is disrupted in A375 MBMs, vemurafenib achieved greater antitumor efficacy against MBMs in Abcb1a/b;Abcg2 −/− mice compared with WT mice. Concordantly, P‐gp and BCRP are expressed in MBM‐associated brain endothelium both in patients and in A375 xenografts and expression of these transporters limited vemurafenib penetration into A375 MBMs. Although initially responsive, A375 MBMs rapidly developed therapy resistance, even in Abcb1a/b;Abcg2 −/− mice, and this was unrelated to pharmacokinetic or target inhibition issues. Taken together, we demonstrate that both intrinsic and acquired resistance can play a role in MBMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, China.
- Shandong Provincial Key Laboratory of Brain Function Remodeling, Qilu Hospital, Shandong University, China.
- Division of Psychosocial Sciences and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Mouse Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/MC Slotervaart Hospital, Amsterdam, The Netherlands.
ORCID-Profile: Laura Esmee Kuil, Jos Hendrik Beijnen, Olaf van Tellingen, Mark Cornelis de Gooijer
Förderung
- Stichting STOPhersentumoren.nl
Zitieren
APA
Zhang, P., Kuil, L. E., Buil, L. C. M., Freriks, S., Beijnen, J. H., van Tellingen, O., & de Gooijer, M. C. (2024). Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases. FEBS Open Bio, 14(1), 96-111. https://doi.org/10.1002/2211-5463.13730
Vancouver
Zhang P, Kuil LE, Buil LCM, Freriks S, Beijnen JH, van Tellingen O, et al. Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases. FEBS Open Bio. 2024;14(1):96-111. doi:10.1002/2211-5463.13730
BibTeX
@article{Zhang2024,
author = {Zhang, Ping and Kuil, Laura Esmee and Buil, Levi Conrad Maria and Freriks, Stephan and Beijnen, Jos Hendrik and van Tellingen, Olaf and de Gooijer, Mark Cornelis},
title = {Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases},
journal = {FEBS Open Bio},
year = {2024},
volume = {14},
number = {1},
pages = {96--111},
doi = {10.1002/2211-5463.13730}
}
EUVIMED